Please login to the form below
myelofibrosis
This page shows the latest myelofibrosis news and features for those working in and with pharma, biotech and healthcare.
Rare cancer specialists Sierra Oncology acquired by GSK for £1.5bn
Unification will help to uphold and progress promising Momelotinib treatment which targets myelofibrosis. ... Momelotinib offers a differentiated treatment option that could address the significant unmet medical needs of myelofibrosis patients with
Latest news
-
Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz
The increase was driven by the strong performance of its heart failure combination Entresto (sacubitril/valsartan) which was up by 44%, psoriasis antibody Cosentyx (secukinumab) up by 22%, myelofibrosis drug Jakavi
-
MorphoSys expands oncology pipeline with $1.7bn acquisition of Constellation Pharmaceuticals
Pelabresib, a potentially first-in-class BET inhibitor, is currently being evaluated in phase 3 clinical trials for the bone marrow cancer myelofibrosis.
-
FDA fast-tracks review of Incyte’s Jakafi for chronic GVHD
It is approved across a number of indications, including for the treatment of polycythemia vera (PV), intermediate- or high-risk myelofibrosis (MF) and post-essential thrombocythemia MF.
-
Incyte’s JAK inhibitor cream clears second eczema trial
Ruxolitinib is already on the market in oral form under the Jakafi/Jakavi brand names as a treatment for myelofibrosis, a type of bone marrow cancer.
-
BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel
It was cleared for use in myelofibrosis – a rare bone marrow disorder. ... Some analysts have predicted that Inrebic could also become a $1bn product in myelofibrosis, despite a black-box warning on its label for a serious and life-threatening brain
More from news
Approximately 10 fully matching, plus 43 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis
-
Deal Watch January 2018
Celgene will pay approximately $1.1bn upfront for Impact and further contingent payments based on regulatory approval for fedratinib in myelofibrosis and other indications could amount to $1.4bn. ... Acquisition company - remaining 90%. 9, 000. Impact
-
Pharma deals in August 2015
Acquisition ‐ company. 1300. Promedior. BMS. PRM 151 recombinant pentraxin‐2 protein for idiopathic pulmonary fibrosis and myelofibrosis.
-
Pharma deals during November 2014
Good news at last. Days after finally getting the FDA's go-ahead to resume development of its lead candidate, imetelsta, for myelofibrosis and myelodysplastic syndrome, Geron has signed a deal
-
NICE and ‘ultra orphans’
It won't, for example, affect medicines such as Novartis' treatment for myelofibrosis, a rare blood cancer of which there are only around 0.4 cases of the condition per 100,
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Boston Biomedical appoints commercial head
At Incyte, she established the company's commercial operations and successfully launched Jakafi (ruxolitinib) for myelofibrosis as part of a collaboration with Novartis.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
The other side of … blood cancer
He just never makes any time for me.”. Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called myelofibrosis.
-
THE OTHER SIDE OF...BLOOD CANCER
Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called myelofibrosis.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- Create Health Showreel
- AstraZeneca acquires TeneoTwo in a deal worth up to $1.27bn
- Cancer Research UK urges government to realise ‘science superpower’ ambitions as new report highlights ‘huge’ economic value
- Novartis UK launches first health-tech investor partnership to address cardiovascular care
- UK government invests £175m to ‘supercharge’ clinical research
- A creative awakening – how pharma is bringing innovation to the patient journey
- European Commission approves potential new treatment for Pompe disease
- Sanofi Global Health unveils new nonprofit Impact brand
- J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Novartis UK launches first health-tech investor partnership to address cardiovascular care
PMHub
Graphite Digital
We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...
Latest intelligence
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
